Cognos Therapeutics
  • ABOUT
    • MISSION
    • BOARD of DIRECTORS
    • MANAGEMENT TEAM
    • IP MANAGEMENT
    • NEURO-ONCOLOGY BOARD
    • REGULATORY AND COMPLIANCE
  • CLINICAL RELEVANCE
    • FOURTH MODALITY
  • PUBLICATIONS
  • NEWS
  • SHAREHOLDER PORTAL
    • SHAREHOLDER INFORMATION
  • CONTACT
Select Page

Logowithtagline.compress.gd

by cognosadminteam | Jan 12, 2018 | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Recent Posts

  • Cognos Therapeutics, Inc. To Be Publicly Listed On Nasdaq
  • Labroot’s Report Focuses on the Need To Develop Better Methods To Deliver Therapeutics to the Brain
  • Cognos Co-Founder and CIO Josh Shachar Discusses The Evolution of the Cognos Vision
  • Cognos Engages Maxim Group for Investment Banking and Financial Advisory Services
  • Cognos Announces Addition of New Clean Room To Expand Its Development Capabilites.

Recent Comments

    Archives

    • January 2023
    • January 2022
    • November 2021
    • October 2021
    • February 2019
    • January 2018
    • July 2017
    • September 2016
    • March 2015

    Categories

    • News

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Cognos Therapeutics, Inc.

    10604 S La Cienega Blvd.
    Inglewood, CA 90304
    T: 310-641-2700
    E: info@cognosthx.com

    ADDITIONAL INFO

    Privacy Policy
    Terms of Use
    • Facebook
    • Twitter
    • Instagram
    • RSS

    Designed by Elegant Themes | Powered by WordPress